Letetresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Myxoid Liposarcoma. According to GlobalData, Phase II drugs for Myxoid Liposarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Letetresgene autoleucel LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Letetresgene autoleucel overview
Letetresgene autoleucel (GSK-3377794) was under development for the treatment of advanced multiple myeloma (Kahler's Disease), recurrent epithelial ovarian, primary peritoneal, fallopian tube carcinoma. It is administered through intravenous route. The drug candidate is a cellular immunotherapy, in which the T cells are engineered to recognize the cancer-testis antigen, NYESO-1. Autologous T cells are developed based on Affinity Enhanced TCR Technology platform. The therapeutic candidates were also under development for prostate and liver cancer. It was also under development for the treatment of metastatic melanoma. It was also under development for gastro-esophageal cancer and relapsed multiple myeloma,synovial sarcoma, myxoid round cell liposarcoma and non-small cell lung cancer.
Adaptimmune Therapeutics overview
Adaptimmune Therapeutics (Adaptimmune) is a clinical-stage biopharmaceutical company that develops innovative T-cell therapy products for the treatment of cancer. The company product pipeline includes afami cel, ADP-A2M4CD8 and ADP-A2AFP. It treats synovial sarcoma, head and neck, urothelial, esophageal, EGJ cancer and hepatocellular carcinoma. Adaptimmune has collaborated with Alpine Immune Sciences, Cell and Gene Therapy Catapult, Center for Cancer ImmunTherapy, Genentech and MD Anderson Cancer Center, among others. The company has operations across the US and the UK. Adaptimmune is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of Letetresgene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.